Navigation Links
Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis

- Topical Therapy Reduces TNF-alpha Production Through Inhibition of PDE-4 Enzyme

PALO ALTO, Calif., June 06, 2007 /PRNewswire/ -- Anacor Pharmaceuticals, a privately held pharmaceutical company, announced today the results from its placebo-controlled Phase 1 trial of AN2728, a first-in-class topical therapy under investigation for the treatment of psoriasis. The trial showed AN2728 to be well-tolerated, with activity comparable to existing topical treatments for psoriasis.

AN2728 is the product of a focused medicinal chemistry effort to create small molecules that inhibit TNF-alpha, the inflammatory cytokine that is the target of the powerful monoclonal antibodies now marketed for the treatment of psoriasis. Company researchers have shown that AN2728 suppresses the phosphodiesterase 4 (PDE4) enzyme, leading to TNF-alpha inhibition.

"This early-stage trial demonstrated definitive anti-inflammatory activity in humans. We are encouraged that the compound decreases TNF-alpha, a cytokine known to be important in psoriasis, by the inhibition of PDE4, a well-validated anti-inflammatory target," said Karl Beutner, Anacor's chief medical officer. "A topical compound that effectively targets TNF-alpha would have great promise, and we intend to initiate further clinical trials to characterize the clinical utility of this drug in psoriasis and other inflammatory skin diseases."

Psoriatic plaques on each of the 12 patients enrolled in the trial were divided into six sections, and each of those sections was treated with a different therapy: AN2728 ointment, AN2728 cream, betamethasone, tacrolimus (Protopic) and vehicle cream and ointment. Using ultrasound, researchers measured the thickness of the inflammatory infiltrate in the psoriatic plaques and also recorded the clinical response based on an investigator global evaluation of disease severity.

As measured by decreases in the thickness of the
'"/>




Page: 1 2

Related medicine technology :

1. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Gen-Probe invests US$5 million in DiagnoCure SAN DIEGO and ... GPRO ) and DiagnoCure Inc. (TSX: CUR) today ... their 2003 license agreement, establishing new FDA submission milestones ... potential of the PCA3-based test for prostate cancer in ...
... 29 The recent announcement of the REDUCE trial results ... optimism to the prostate cancer community as dutasteride (Avodart), a ... lower by 23 percent the risk of prostate cancer in ... Network looks forward to this becoming an additional tool in ...
Cached Medicine Technology:Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 2Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 3Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 4Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 5Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer 2
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
(Date:4/17/2014)... 2014While 94 per cent of Canadians surveyed said they ... for a specific number of genetic conditions, only 80 ... in screening that would sequence their newborns, genomes.,Most newborns ... their first day or two of life in which ... heels and tested for about five to 54 conditions, ...
(Date:4/17/2014)... for more research to be carried out into ... Africa. In a paper in The Lancet ... with colleagues in the department of Parasitology and ... Ohio, University of Cambridge and the Royal Veterinary ... burden of HIV/AIDS and schistosomiasis of children, and ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2
... rheumatoid arthritis (RA), an autoimmune disease marked by chronic ... and the incidence of cancer is complicated. Epidemiologic ... cancers are increased among RA patients, while breast and ... are caused by the nature of RA or by ...
... for downward social mobility, study confirms , , TUESDAY, Aug. ... a downscale neighborhood often go together, a new study ... comes first. , "The more alcohol problems a man ... in, or migrate into, a disadvantaged neighborhood," according to ...
... report cites drop in employer-sponsored coverage , , TUESDAY, ... Americans are without health insurance, according to new U.S. ... trend can be explained by employers who are curtailing ... workers to afford, the report said. , "The number ...
... better diagnoses and therapies, researchers say , , TUESDAY, Aug. ... the brains of multiple sclerosis patients may help predict ... researchers are reporting. , "This is a new ... the tissue of the patient,s lesions," said lead researcher ...
... age 7 were virtually erased, study finds , , TUESDAY, ... during pregnancy and don,t get treatment, their kids face ... suggests that treatment can essentially eliminate that risk. , ... obesity can be completely reversed in these children, said ...
... to be published in an upcoming edition of ... that Pycnogenol (pic-noj-en-all), pine bark extract from the ... as hot flashes, depression, panic attacks, cholesterol and ... transition. The results suggest Pycnogenol may serve as ...
Cached Medicine News:Health News:Biologic treatment for rheumatoid arthritis and the risk of cancer 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 3Health News:Record Number of Americans Lack Health Insurance 2Health News:Record Number of Americans Lack Health Insurance 3Health News:Record Number of Americans Lack Health Insurance 4Health News:Brain Lesions Predict MS Progression 2Health News:Brain Lesions Predict MS Progression 3Health News:Treating Diabetes During Pregnancy Could Lead to Thinner Kids 2Health News:New study: Pine bark reduces perimenopausal symptoms 2
Cold light source dual outlet....
The 9100 is a truly affordable 100 Watt xenon light source providing accurate color and brightness. This xenon light source is ideal for surgery centers, evaluations or general office use....
... the brightest and most versatile light source ... 300 Watts, this unique light source allows ... an illuminated instrument or two UltraLite Headlights ... delivers bright, white light that is as ...
Loupe KS is achieved by a special system carrier....
Medicine Products: